Shanghai Fosun to buy India's Gland in $1.4B deal that will face scrutiny

China's Shanghai Fosun Pharmaceutical Group has reportedly won a bidding war for India's privately held injectable maker Gland Pharma in a rare cross-border deal that brings together companies from two Asian powerhouses in generics manufacturing.

A trading halt to Shanghai Fosun's shares in Hong Kong signals the deal, and Reuters and the Economic Times have reported some details.

But no official announcement has been made regarding the Hyderabad-based company backed by private equity player KKR, which along with the drugmaker's founders controls 95% of Gland.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Other companies reportedly in the bidding included Baxter International, Torrent Pharma and buyout firm Advent International--with earlier reported estimates of a valuation of $1.5 billion.

The deal will test India's new rules on foreign investment in the pharmaceutical sector approved in June that allow investment of up to 74% in companies by notifying regulators of the transaction--but approval from agencies such as the Foreign Investment Promotion Board is not required. Previously, the level was set at 49% for such transactions.

India and China have had uneasy commercial ties that stem from a brief but bloody border war in 1962 that lingers over relations.

Companies such as Huawei that in the past have sought toeholds in India's software companies have faced regulatory scrutiny, and in the case of pharmaceuticals, Indian generic drugmakers repeatedly complain about active pharmaceutical ingredient imports from China dominating the market.

For Shanghai Fosun, the purchase would win it a company that operates globally and has approvals with U.S. and European regulators in manufacturing covering injectables across container-types and fillings.

- here's the story from Reuters

Related Articles:
India ups direct foreign investment cap in drug companies to 74% from 49%
China's Shanghai Fosun joins race to buy India injectables maker Gland

Read more on

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.